Xencor Q2 2023 revenue $45.5M up 51% YoY; net loss narrows to $22M; pipeline advances

Xencor Inc

2023-Q2 EPS reported -$1.38 revenue$64,485,000

Revenue $45.5M (vs $30.2M Q2 2022), net loss $22.0M ($0.37/diluted) vs $34.0M loss ($0.57) prior.
Cash, equivalents and marketable securities $531.4M at June 30, 2023, down from $613.5M at Dec 31, 2022.
Royalty revenue from Alexion's Ultomiris $11.2M; $10M milestone from Zenas for obexelimab Phase 3 start.
R&D expenses $60.1M, up 28% YoY; guidance projects year-end cash $425-475M, funding through 2025.
Vudalimab Phase 2 front-line NSCLC expected by year-end; XmAb662 Phase 1 started; XmAb541 IND planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xencor Inc reported second quarter ended June 30, 2023 results: revenue $45.5 million.

Period: second quarter ended June 30, 2023
Revenue: $45.5 million
Result: reported results

Exact text from the filing

Total revenue for the second quarter ended June 30, 2023 was $45.5 million

View on SEC.gov

Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.